CDMO Experic is adding a thin film freezing manufacturing line based on technology owned by TFF Pharmaceuticals at its Cranbury, NJ, USA cGMP facility, according to TFF. Completion of Experic’s TFF line, which adds a third cGMP manufacturing site for TFF, is expected in the second quarter of 2021.
In September 2020, TFF announced that it will advance its voriconazole inhalation powder into Phase 2 development for the treatment of invasive pulmonary aspergillosis. In 2020, the company has gotten orphan drug status for its dry powder tacrolimus for for the prevention of lung transplant rejection; said that it is working on a universal flu vaccine in partnership with two US universities; and announced an agreement with the US military for development of dry powder vaccines. In addition, Union Therapeutics recently acquired an option to license TFF’s dry powder niclosamide.
TFF Pharmaceuticals President and CEO Glenn Mattes said, “This expansion of our manufacturing operations at Experic gives us the capability and capacity to develop and produce additional products currently in assessment with pharmaceutical company partners. Experic has been a terrific partner for us because of their domain expertise in dry powder inhalation products. They also provide us with unique downstream encapsulation technology that rounds out the specialized manufacturing requirements of our dry powder inhalation therapies.
Experic Chairman and CEO Jeffrey P. McMullen commented, “The entire Experic team is thrilled to be working with TFF Pharmaceuticals and supporting development and manufacturing activities using its Thin Film Freezing (TFF) technology. We share their excitement in the continued advancement and expansion of their technology and business.”
Read the TFF Pharmaceuticals press release.
